Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Bone marrow edema (BME) is a significant imaging finding in musculoskeletal and emergency radiology, often associated with trauma or nontraumatic etiologies such as inflammation, infection, or neoplasms. Magnetic resonance imaging (MRI) remains the gold standard for BME evaluation. However, dual-energy CT (DECT) has emerged as a valuable alternative due to its faster acquisition times, lower costs, and more rapid access in emergency settings (when compared with MRI), facilitating timely decision-making when MRI is impractical or contraindicated. Despite its benefits, accurate interpretation of BME on DECT requires careful understanding of its limitations and potential pitfalls. This article addresses the technical and clinical challenges in DECT-based BME assessment and proposes strategies to enhance diagnostic accuracy.A review of the literature was performed by searching the PubMed and ScienceDirect databases, using the keywords ("DECT" or "Dual-Energy") and ("BME" or "bone marrow edema") and ("musculoskeletal" or "bone" or "skeleton") for the title and abstract query. The inclusion criteria were scientific papers presented in the English language. Exclusion criteria included articles which had no relevant focus on BME and case reports. Of the 168 articles initially identified, 75 were deemed relevant and were reviewed in detail. Insight from this literature search and the authors' clinical experience forms the basis of this review, highlighting key pitfalls and strategies for accurate BME interpretation.DECT provides significant advantages for detecting BME, such as material-specific color overlays and high anatomical correlation. However, key pitfalls include the misinterpretation of artifacts, difficulties in cases of severe displacement or sclerosis, and challenges posed by imaging artifacts in large-sized patients or those with metallic implants. Radiologists can improve diagnostic accuracy by understanding the limitations and pitfalls of DECT, and by adopting the solutions outlined in the article to optimize its use. · DECT effectively identifies BME in both traumatic and non-traumatic conditions, with sensitivity and specificity comparable to magnetic resonance imaging (MRI).. · Key interpretation pitfalls include artifacts from photon starvation, metallic implants, severe displacement, and motion, as well as limitations in algorithm processing.. · Misdiagnoses can arise due to mimics of BME, such as sclerosis, red marrow, or pathological fractures, necessitating clinical and imaging correlation.. · Parameter optimization (e.g., spectral FOV, kernel selection, image calibration) enhances diagnostic accuracy and reduces errors.. · Yap JA, Ong YX, Weber M. Pitfalls in Bone Marrow Edema Interpretation on Dual-Energy CT: Challenges and Solutions. Rofo 2025; DOI 10.1055/a-2653-9256.

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-2653-9256DOI Listing

Publication Analysis

Top Keywords

bone marrow
12
marrow edema
12
bme
9
pitfalls bone
8
edema interpretation
8
interpretation dual-energy
8
dual-energy challenges
8
challenges solutions
8
magnetic resonance
8
resonance imaging
8

Similar Publications

Unlabelled: B-cell lymphomas are highly aggressive forms of lymphoma that commonly present with lymphadenopathy, systemic "B" symptoms, or organ involvement making them easy to recognize; however, a small percentage of B-cell lymphomas can present without any typical symptoms or evidence of lymphadenopathy, resulting in delayed recognition and management. Isolated thrombocytopenia without anaemia or leukopenia is an unusual presentation of B cell lymphomas and may be misdiagnosed as immune thrombocytopenia (ITP). Given the rarity of this presentation, we wish to report a case of a 76-year-old female who presented with palpitations, shortness of breath, and recurrent chest infections.

View Article and Find Full Text PDF

Background: Blinatumomab and inotuzumab ozogamicin (InO) are B-cell targeted agents used in the frontline and relapsed/refractory treatment of B-cell acute lymphoblastic leukaemia (B-ALL). Blinatumomab, a bispecific T-cell engager that targets CD19 and CD3, and InO, an antibody-drug conjugate targeting CD22, have both shown efficacy. However, recent reports have noted lineage conversion as a complication when these agents are used individually or sequentially.

View Article and Find Full Text PDF

Severe aplastic anemia (SAA) is a life-threatening bone marrow failure syndrome that is caused primarily by immune-mediated destruction of hematopoietic stem cells. Traditional treatment relies on immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporine (CSA). However, the toxicity and limited availability of ATG have spurred interest in ATG-free regimens.

View Article and Find Full Text PDF

NSG-SGM3 humanized mouse models are well-suited for studying human immune physiology but are technically challenging and expensive. We previously characterized a simplified NSG-SGM3 mouse, engrafted with human donor CD34 hematopoietic stem cells without receiving prior bone marrow ablation or human secondary lymphoid tissue implantation, that still retains human mast cell- and basophil-dependent passive anaphylaxis responses. Its capacities for human antibody production and human B cell maturation, however, remain unknown.

View Article and Find Full Text PDF

Background: Mixed-phenotype acute leukemia (MPAL) is a rare acute leukemia for which data are currently not available to guide therapy. It has a poor outcome, particularly in elderly patients.

Case Presentation: We report the successful use of venetoclax/azacitidine as treatment for a treatment-naive elderly patient with early T-cell precursor (ETP)/myeloid MPAL.

View Article and Find Full Text PDF